# Sermorelin Research: Mechanism, GH/IGF-1 Data, and the Evidence Limits > The sermorelin research record: the GHRH-receptor mechanism, GH/IGF-1 findings in children and older adults, cognition and body-composition data, side effects, and where the adult evidence stops. Mechanism, dose-response, cognition, body composition, and safety — each finding attributed to its source and kept apart from the marketing. ## Start here This page works through what sermorelin research has actually measured. The mechanism comes first — how the peptide tells the pituitary to release growth hormone (GH) — then the human studies in children and older adults, then the contested edges: cognition, sleep, fat, muscle, and side effects. Where a number appears, a study is named. Where the evidence is thin or borrowed from a related compound, that is said plainly. The short rule for the whole page: sermorelin's strongest data is its oldest and most boring; the exciting adult claims are the least supported. ## Sermorelin mechanism of action: the GHRH receptor and pulsatile GH Sermorelin binds the GHRH receptor (GHRH-R), a class B G-protein-coupled receptor on the growth-hormone-producing cells (somatotrophs) of the anterior pituitary. Activation couples through Gs to adenylate cyclase, raising cyclic AMP (cAMP, a cell's internal "go" messenger) and activating protein kinase A (PKA). The result is increased GH gene transcription and pulsatile release of the body's own growth hormone [13]. The defining feature is *where* it acts. By stimulating the pituitary rather than supplying GH from outside, sermorelin keeps the body's feedback loops in play: somatostatin (the hypothalamic brake on GH) and IGF-1 (a growth signal the liver makes when GH rises, which also feeds back to slow GH) both continue to regulate output [4]. That is why the GH it elicits stays pulsatile and feedback-limited rather than flat and supraphysiologic — an editorial framed this as the physiologic argument for secretagogues over recombinant hormone [4]. The 2025 Nature Reviews Endocrinology synthesis of GHRH and its analogues covers this receptor biology and the GH/IGF-1 axis in depth [13]. ## Does sermorelin work in the research literature? In its approved pediatric use, yes, on the endpoint it was studied for. Once-daily subcutaneous GHRH(1-29) accelerated first-year height velocity in GH-deficient children from about 4.1 cm/year to roughly 7-8 cm/year, without excessive IGF-1 generation [1]. In older men, 0.5 mg and 1 mg subcutaneously twice daily for 14 days produced dose-related rises in 24-hour GH and IGF-1; after the high dose, those parameters were statistically indistinguishable from young men's, with no change in fasting glucose [2]. Adult anti-aging efficacy is a different and far weaker case. The Annals of Internal Medicine editorial that surveyed secretagogue use for aging concluded it was "not yet ready for prime time" [5]. So "does it work" splits cleanly: it raises GH and IGF-1 in studied populations, which is mechanism doing what mechanism should; whether that produces the durable clinical benefits marketed to adults is not established. ## Onset timelines reported in sermorelin studies A single dose of GHRH(1-29) elevates serum GH for roughly 3 hours despite the peptide's rapid clearance from plasma [3]. In the older-men study, the dose-related GH and IGF-1 increases were measured over a 14-day course [2]. Single nightly injections in healthy elderly men were studied for their effect on the GH/IGF-1 axis over time [10]. Timelines longer than these endpoints come from related-analog studies, not from extended sermorelin trials — so claims about "results in X weeks" generally extrapolate beyond the sermorelin-specific record. ## Sermorelin and IGF-1 Sermorelin raises IGF-1 in studied populations, and it does so within feedback limits. In older men, 14 days of subcutaneous GHRH(1-29) produced dose-related increases in 24-hour GH and IGF-1 [2]. A related GHRH-analog trial raised IGF-1 by 117%, kept within the physiologic range, over 20 weeks [6]. A GHRH analog has also been shown to alter endogenous GH pulsatility and insulin sensitivity in healthy men, confirming that GHRH-axis stimulation modulates both secretory dynamics and glucose handling [11]. The recurring point is that the IGF-1 rise stays regulated by the body's own brakes rather than running supraphysiologic. ## GHRH and cognition in older adults In a randomized, double-blind, placebo-controlled trial of 152 older adults — 66 of them with mild cognitive impairment — 20 weeks of a daily subcutaneous GHRH analog (tesamorelin, 1 mg/day before bedtime) had a favorable effect on cognition (P=0.03; executive function P=0.005), increased IGF-1 by 117% within the physiologic range, and reduced percent body fat by 7.4%, with mild adverse events [6]. This is the strongest controlled cognition signal in the GHRH-analog literature. It used the stabilized analog rather than native sermorelin, so it is class-level evidence for GHRH-axis stimulation, not a sermorelin trial — an honest distinction the popular summaries often drop. ## Sermorelin, GHRH, and the brain Beyond cognition scores, GHRH administration has measurable neuroendocrine effects. The controlled trial above reported a favorable cognitive effect in older adults [6]. GHRH also has documented sleep-promoting effects in normal men, which is the basis for the sleep section below. The brain effects are real in the studied designs but bounded: they are neuroendocrine and cognitive endpoints in specific populations, not a general nootropic claim. ## Sermorelin, GHRH, and slow-wave sleep GHRH has documented sleep-promoting effects — specifically on slow-wave (deep) sleep — in normal men, but those effects depend on the time of administration [12]. The body's largest natural GH pulse occurs shortly after sleep onset, which is why nocturnal dosing was the design choice in GHRH sleep-endocrine work [10][12]. The everyday report that sermorelin sometimes seems to disrupt rather than deepen sleep is consistent with the timing-dependence the studies describe: GHRH given out of phase with the natural pulse is a different stimulus than GHRH given to augment it. ## Sermorelin, body composition, and fat: what was measured The fat and body-composition signal in this literature is real but mostly *not* sermorelin's. Pulsatile GH secretion contributes to lipolysis (fat breakdown) in fasting humans, and the stabilized GHRH analog tesamorelin significantly reduced visceral fat in HIV-associated fat accumulation [6][11]. In the cognition trial, the GHRH analog reduced percent body fat by 7.4% over 20 weeks [6]. Direct, controlled visceral-fat or weight-loss trials of sermorelin *itself* are lacking. The signal is therefore class-level GH-axis evidence — which is exactly why the adult body-composition marketing outpaces the sermorelin-specific record. ## Is sermorelin effective for weight loss in studies? There are no controlled sermorelin weight-loss trials. The body-composition evidence comes from GHRH-axis stimulation studies — tesamorelin reducing visceral adipose tissue, and pulsatile GH supporting fasting lipolysis — rather than from sermorelin trials with weight as an endpoint [6][11]. Stated plainly: anti-aging and body-composition marketing outpaces the sermorelin-specific evidence, and a careful reader should treat "sermorelin for weight loss" as a class-level inference, not a demonstrated result. ## Sermorelin and muscle: what is and is not established There is no sermorelin muscle-hypertrophy trial in this record. GHRH-axis stimulation raises IGF-1, an anabolic mediator [2][6], which is the mechanistic basis for muscle claims — but reviews note that GH/IGF-1 elevation alone does not reliably translate into functional muscle gains [15]. Muscle-building claims therefore run ahead of the sermorelin-specific evidence, in the same pattern as the weight-loss claims: a plausible mechanism, no controlled outcome trial. ## Sermorelin side effects and tolerability in the research literature Reported effects in the GHRH and secretagogue literature are generally mild — injection-site reactions and flushing are the commonly described tolerability findings, and the cognition trial recorded only mild adverse events [6]. In older men, 14 days of dosing produced no change in fasting glucose [2]. The recognized theoretical concern is oncologic: because GH and IGF-1 are mitogenic (they drive cell division), chronically raising them is theorized to carry cancer risk, a standard caution for any GH-axis intervention. Long-term safety data specifically for adult anti-aging use remain limited [5]. A 2026 structured review of injectable peptides in sports medicine likewise found GH-axis secretagogues investigational, with uncertain safety profiles and product-quality concerns [15]. ## Doping prohibition and detection Sermorelin is prohibited in sport. Growth-hormone secretagogues, including GHRH analogs, appear on the WADA Prohibited List under hormone and metabolic modulators (S2), banned in- and out-of-competition; a 2026 critical review classifies sermorelin among GHRH-analogue peptides marketed for performance enhancement [8]. Detection is analytically difficult because the peptides resemble endogenous hormones and clear quickly, but anti-doping science has responded: a decade of LC-mass-spectrometry method development extended detection windows using peptide metabolites [8], an automated dried-blood-spot LC-HRMS method now detects 46 lower-mass doping agents including GH-secretagogues [9], and longitudinal IGF-1 and GH-2000-score biomarker monitoring detected GHRH administration in studied subjects [7]. The [anti-doping and detection status](/faq#doping) FAQ covers the practical questions. --- A premium-Swiss reading of the GHRH(1-29) record — the pulsatile-GH mechanism, the studied doses, and the WADA-prohibited status set in disciplined whitespace and cited to source; no clinic behind the monograph and nothing here dispensed, prescribed, or sold.